A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients

dc.contributor.authorParker, Mitchell J.
dc.contributor.authorKim, Rachel C.
dc.contributor.authorBarrio, Martin
dc.contributor.authorSocas, Juan
dc.contributor.authorReed, Lawrence R.
dc.contributor.authorNakeeb, Attila
dc.contributor.authorHouse, Michael G.
dc.contributor.authorCeppa, Eugene P.
dc.contributor.departmentSurgery, School of Medicineen_US
dc.date.accessioned2022-02-21T18:55:02Z
dc.date.available2022-02-21T18:55:02Z
dc.date.issued2021
dc.description.abstractIntroduction Patients with higher postoperative infection risk undergoing ventral hernia repair (VHR) have limited options for mesh use. Biosynthetic mesh is intended to utilize the durability of synthetic mesh combined with the biocompatibility of biologic mesh. We sought to assess the outcomes of a novel biosynthetic scaffold mesh for VHR in higher risk patients over a 12-month postoperative period. Methods Two cohorts of 50 consecutive patients who underwent VHR with TELA Bio OviTex biosynthetic or synthetic mesh were retrospectively compared. Endpoints included surgical site occurrence (SSO), readmission rate, and hernia recurrence following VHR at 12 months postoperatively. Results OviTex mesh placement was associated with higher risk Ventral Hernia Working Group (VHWG) distribution and more contaminated CDC wound class distribution compared to synthetic mesh placement (VHWG grade 3: 68% vs. 6%, p < 0.001; CDC class > I: 70% vs. 6%, p < 0.001). Additionally, concomitant procedures were performed more often with OviTex mesh placement than synthetic mesh placement (70% vs 10%, p < 0.001). The OviTex mesh performed comparably to synthetic mesh in terms of incidences of SSO (36% vs 22%, p = 0.19), readmission rates (24% vs 14%, p = 0.31), and hernia recurrence (6% vs 12%, p = 0.74). On further evaluation, patients who developed SSO with OviTex mesh (n = 18) had a 17% hernia recurrence whereas those with synthetic mesh (n = 11) had an associated 55% hernia recurrence (p = 0.048). Conclusions The OviTex biosynthetic mesh was used in higher risk patients and performed similarly to synthetic mesh in regards to rate of SSO, readmissions, and hernia recurrence. Furthermore, patients who developed SSO with Ovitex mesh were significantly less likely to have hernia recurrence than those with synthetic mesh. Overall, the data suggest that biosynthetic mesh is a more desirable option for definitive hernia repair in higher risk patients.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationParker, M. J., Kim, R. C., Barrio, M., Socas, J., Reed, L. R., Nakeeb, A., House, M. G., & Ceppa, E. P. (2021). A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients. Surgical Endoscopy, 35(9), 5173–5178. https://doi.org/10.1007/s00464-020-08009-1en_US
dc.identifier.urihttps://hdl.handle.net/1805/27896
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s00464-020-08009-1en_US
dc.relation.journalSurgical Endoscopyen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectventral hernia repairen_US
dc.subjecthernia recurrenceen_US
dc.subjectbiosynthetic meshen_US
dc.titleA novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patientsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Parker_2021_novel.pdf
Size:
598.61 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: